PIN80 Evaluating Patient Preferences For Hiv Therapy: Results From A Discrete Choice Experiment In The Uk And Germany  by Murray, M. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A279
EQ-5D Index and EQ-VAS; these are standardized, preference-based measures of 
health. Results were reported in descriptive and stratified analyses. Linear regres-
sion analyses were performed to determine the independent associations with 
the EQ-5D. Results: There were 297 matched physician and patient response 
forms. Mean patient age was 50 years and 64% were male. Mean EQ-5D Index was 
0.764 (SD= 0.283; range= -0.199-1.000). Mean EQ-VAS was 65.85 (SD= 21.00; 
range= 5-100). EQ-5D Index and EQ-VAS scores were significantly lower with wors-
ening disease severity. Among patients who had completed treatment, EQ-5D 
scores were higher for patients who achieved sustained virologic response (SVR) 
compared to those who did not (EQ-5D Index= 0.873 vs. 0.660, p-value= 0.0035). 
Regression models showed higher age and worsening disease severity were sig-
nificantly associated with lower EQ-5D Index and EQ-VAS scores. ConClusions: 
In a cross-sectional sample of HCV patients in France, utilities are linearly and 
significantly associated with disease progression, SVR, and age. This informa-
tion will be used to understand the benefits of treating patients and preventing 
disease progression.
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objeCtives: In 2012, the US Centers for Disease Control and Prevention published 
recommendations of one-time Hepatitis C virus (HCV) screening for adults born 
during 1945 through 1965. Evaluating U.S. HCV populations by birth segment may 
provide insights that could be increasingly relevant to payers and health care 
providers. Methods: Unique respondent data from the U.S. National Health and 
Wellness Survey from 2009-2012 were analyzed. Individuals aged ≥ 18 years who 
self-reported a Hepatitis C diagnosis were stratified into 3 cohorts based on birth 
year: pre-1946, 1946-1964, and post-1964. Characteristics, treatment rates, QOL 
(SF-12/36), and activity impairment (WPAI) were described. Results: Individuals 
born between 1946-1964 represented 64.6% of respondents with Hepatitis C (13.0% 
were older; 22.3% younger). The 1946-1964 cohort had a higher proportion of males 
than the younger population (65.3% vs. 59.3%, respectively; p< 0.05); 64.2% pre-1946 
were male. Insured status was higher (p< 0.05) in the older cohort (96.5%) versus 
the 1946-1964 (75.5%) or younger (70.2%) cohort. Reported current HCV treatment 
use was lower (p< 0.05) in the older cohort (3.2%) versus 1946-1964 (10.7%) or post-
1964 (21.4%). More than half in each cohort were treatment naïve (64.2% pre-
1946; 53.5% 1946-1964; 53.4% post-1964). A lower (p< 0.05) proportion (10.3%) of 
treatment naïve respondents born pre-1946 had a prior doctor recommendation 
for HCV therapy (versus 21.0% 1946-1964 or 21.1% post-1964). Mean percentage 
activity impairment was lower (p< 0.05) among pre-1946 cohort (34.4%) versus 
1946-1964 (45.3%) or post-1964 (45.1%). Mean Mental Summary Scores worsened 
from oldest to youngest cohorts (pre-1946= 50.6; 1946-1964= 43.8; post-1964= 39.5). 
Mean Physical Summary Scores were higher for the younger cohort (43.6) versus 
1946-1964 (40.2) or pre-1946 (41.2). ConClusions: In this Hepatitis C population 
analyzed by birth segment, individuals born 1946-1964 represented the largest 
segment of the population. Results suggest that differences by birth cohort may 
exist within this population regarding their characteristics, treatment rates, and 
patient-reported outcomes.
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objeCtives: No standardized methods to measure outcomes related to commu-
nity-acquired bacterial pneumonia (CABP) have been developed since release of 
the FDA Patient Reported Outcome (PRO) Guidance. The purpose of this literature 
review was to identify signs, symptoms, and measurement tools associated with 
patient experience of CABP. The results will be used to inform the development of 
a standardized measurement tool for CABP that is consistent with the FDA PRO 
Guidance. Methods: A search was conducted using OVID. MEDLINE (1946-present) 
and EMBASE (1988-2012) were searched using terms related to signs and symp-
toms of CABP and existing measurement and diagnostic tools. Results: The search 
identified 2158 abstracts. 940 were excluded based on pre-specified criteria. The 
remaining 1218 articles were scrutinized for eligibility resulting in 39 meeting the 
inclusion criteria. Thirty-four articles focusing on CABP signs and symptoms were 
identified in the literature. The most commonly reported symptoms were cough, 
chest pain, dyspnea, sputum production, and fatigue. The literature revealed that 
generic PRO instruments and an interviewer-administered measure including 10 
CABP symptoms have been used in CABP studies. Four CABP-specific instruments 
that assess patient-reported symptoms revealed notable methodological limitations 
and these were developed prior to the FDA PRO Guidance. ConClusions: There is 
a paucity of evidence on the most well-defined, reliable, reproducible, and feasible 
method for measuring efficacy outcomes in CABP trials. Establishing an appropri-
ate PRO endpoint for CABP is essential. Existing CABP-specific instruments were 
identified, however, they have methodological limitations, and were all developed 
prior to the FDA PRO Guidance. There is a need to develop a new PRO instrument in 
accordance with FDA guidance for PRO measures. The instrument should address 
limitations of current tools and accurately capture data on concepts and outcomes 
most important to patients.
initiated STRs; 1,681 (47%) initiated MTRs. Median persistence (95% confidence 
interval) was 36.5 (31.3, 38.9) months on STRs and 13.2 (11.9, 15.0) months on MTRs 
(Difference 23.3; P< 0.001).Within the subgroups persistent for the first 6 months, 
median persistence on MTRs was 26.1 (24.2, 28.3) and on STRs was 47.6 (41.2, 
54.3) months. Limiting the MTR analysis to those patients who had persistence ≥ 
6 months still fell short of the overall STR persistence (P< 0.001). ConClusions: 
Patients receiving an STR regimen had significantly longer median persistence, 
by almost two years, compared to those receiving MTRs. Even those patients who 
persisted on an MTR for the first 6 months experienced shorter overall persistence 
than those receiving an STR.
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objeCtives: The aims of this study were to (1) Estimate the relative strength of 
preferences for different attributes of Anti Retroviral Therapy (ART) using a stated 
preference discrete choice experiment (DCE) and (2) incorporate findings from quali-
tative research to supplement the data from the DCE. Methods: A European study 
in France, Italy, Spain, Germany and the UK was undertaken with an estimated1500 
PLWH designed to elicit patients’ strength of preference for different attributes 
of ARTs. This work presents the results from the UK and Germany. Participants 
were given a series of choice-style questions which presented hypothetical ARTs. 
Qualitative data were collected separately through individual interviews (n= 48) 
with PLWH recruited from HIV clinics in the UK and Germany. Results: In total, 
549 patients participated in the DCE (249 in UK) and (300 in Germany). The results 
showed that a rapid improvement in CD4 count and viral load were treatment attrib-
utes valued most highly by patients (UK: OR= 0.79; CI= 0.69-0.90; P< 0.001. Germany: 
OR= 0.79; CI= 0.71-0.87; P< 0.001). In addition, the absence of side effects such as diar-
rhoea was also valued highly (UK:OR= 0.57 CI= 0.51-0.65, p< 0.001. Germany: OR= 0.79, 
CI= 0.72-0.86; P< 0.001), as well as lower risk of long- term toxicities such as decline 
in renal function and an increase of cardiovascular risk (UK: OR= 0.30 CI= 0.25-
0.35, p< 0.001. Germany: OR= 0.55, CI= 0.48-0.63, p< 0.001). Other treatment attributes 
driving patient preference included reduction in treatment failure, absence of food 
restrictions with ART, and fewer drug-drug interactions (DDIs). The main differ-
ence between the German and UK results is that German patients did not value 
the absence of DDIs, the qualitative data suggests that they felt that these issues 
are being managed by their clinician. ConClusions: The DCE demonstrated that 
patients placed a great deal of importance on treatment efficacy as evidenced by 
the importance placed on these attributes.
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objeCtives: Health state utility values (HSUVs) in HIV are a key component of 
economic models that include Quality Adjusted Life years (QALY). There are limited 
HSUVs previously reported in HIV patients from Kenya. The objective of this study 
was to examine the HSUVs by severity of symptoms in an HIV infected popula-
tion. Methods: A Kiswahili translated SF-12 survey was administered to newly 
diagnosed HIV infected patients participating in a randomized, controlled trial in 
Nairobi, Kenya between April and October 2013. Patients were also asked if they were 
experiencing common symptoms of HIV (ie. fatigue, loss of appetite, depression or 
diarrhea) on a scale including no symptoms, mild, moderate or severe symptoms. 
SF-12 results were scored using Brazier’s SF6D utility algorithm. Mean HSUVs among 
patients reporting severe symptoms, mild/moderate symptoms or no symptoms 
were compared using ANOVA. Results: 135 respondents were included in the anal-
ysis with 7 observations removed due to missing data. HSUvs among asymptomatic 
HIV patients was 0.98 (SD= 0.04), among patients experiencing mild/moderate symp-
toms was 0.89 (SD= 0.12) and among patients experiencing severe symptoms was 
0.73 (SD= 0.16). ANOVA showed significant differences (p< 0.01) between group and 
a post-hoc Tukey test confirmed mean HSUVs were significantly different between 
those reporting severe symptoms and the other categories. ConClusions: This 
study measures HSUVs in a Kenyan cohort of HIV patients and confirms that sig-
nificant differences exist in quality of life between subgroups of these HIV infected 
patients. The utilities are inline with values measured in studies from other set-
tings. These HSUVs may be used to determine QALYs for use in health economic 
HIV research in Kenya.
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objeCtives: France has a high prevalence of chronic hepatitis C (HCV) and clinical 
impacts of the disease are well recognized. Despite this, information on utility 
and health-related quality of life (HRQoL) is limited. While it is generally accepted 
that HCV patients have reduced HRQoL, delineation of these values by disease 
stage and treatment outcome is not clear. These differences are important for 
determining the benefits of treating patients and preventing disease progression. 
This study assessed utility values of HCV patients in France by disease stage and 
treatment outcome. Methods: Physicians treating HCV patients in France were 
recruited to participate in the Hepatitis C Disease Specific Programme®. From 
October 2012 thru January 2013, physicians completed Patient Record Forms for 
10 consecutive patients presenting to their clinic. Information included patient 
demographics, disease stage, and treatment outcome. Patients completed the 
